TOK 8801

Drug Profile

TOK 8801

Latest Information Update: 27 Aug 2002

Price : $50

At a glance

  • Originator Asahi Kasei
  • Developer Asahi Kasei; Nonindustrial source
  • Class Antirheumatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 15 Jan 2001 Asahi Chemical is now called Asahi Kasei
  • 05 May 1997 Phase-II clinical trials for Rheumatoid arthritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top